GDNF receptorα

US7105484B2 · kind B2 · utility

Assignee

• Genentech, Inc. · US

Inventors

• Robert Klein · Palo Alto, US
• Mark Wade Moore · Greenbrae, US
• Arnon Rosenthal · Woodside, US
• Anne M. Ryan · Millbrae, US

Key dates

• Filing date: Nov 2, 2001
• Grant date: Sep 12, 2006
• Expiry date: Dec 8, 2023

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2319/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

GDNFRα, GDNFRα extracellular domain (ECD), GDNFRα variants, chimeric GDNFRα (e.g., GDNFRα immunoadhesin), and antibodies which bind thereto (including agonist and neutralizing antibodies) are disclosed. Various uses for these molecules are described, including methods to modulate cell activity and survival by response to GDNFRα-ligands, for example GDNF, by providing GDNFRα to the cell. Also provided are methods for using GDNFRα, GDNF, or agonists thereof, separately or in complex, to treat kidney diseases.